Front. Public Health Frontiers in Public Health Front. Public Health 2296-2565 Frontiers Media S.A. 10.3389/fpubh.2025.1737084 Correction Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia Lewandrowski Kai-Uwe 1 2 3 4 5 * Blum Kenneth 1 6 7 8 9 10 11 12 * Lewandrowski Alexander P. L. 13 Thanos Panayotis K. 6 14 Pinhasov Albert 1 6 Sharafshah Alireza 1 15 Baron David 1 7 16 Gold Mark S. 17 Dennen Catherine A. 1 18 Elman Igor 1 6 19 Bowirrat Aballa 1 6 Modestino Edward J. 1 8 Zeine Foojan 1 8 20 Jafari Nicole 1 8 21 Sunder Keerthy 1 7 12 22 Makale Milan T. 1 8 23 Giordano John 1 8 9 Gondre-Lewis Marjorie C. 1 24 Lindenau Marco 1 Fuehrlein Brian S. 25 Badgaiyan Rajendra D. 1 8 26 27 Levin Chynna 1 8 28 Schmidt Sergio Luis 4 Fiorelli Rossano Kepler Alvim 4 Division of Personalized Genomics, The Blum Institute of Neurogenetics & Behavior, Austin, TX, United States Department of Orthopedic Surgery, University of Arizona Tucson Campus, Tucson, AZ, United States Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, Colombia Department of Orthopedics, Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil Division of Personalized Pain Research and Education, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ, United States Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel Division of Addiction Research & Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, CA, United States Brain & Behavior Lab, Department of Psychology, Curry College, Milton, MA, United States Division of Recovery and Rehabilitation, JC Recovery and Counseling Center, Hollywood, FL, United States Faculty of Education and Psychology, Institute of Psychology, Eötvös Loránd University, Budapest, Hungary Department of Psychiatry, University of Vermont, Burlington, VT, United States Division of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, United States Department of Biological Sciences, Dornsife College of Letters, Arts & Sciences, University of Southern California, Los Angeles, CA, United States Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Clinical Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, United States Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, United States Department of Psychiatry, Cambridge Alliance, Harvard University School of Medicine, Cambridge, MA, United States Department of Health Science, California State University at Long Beach, Long Beach, CA, United States Department of Applied Clinical Psychology, The Chicago School of Professional Psychology, Los Angeles, CA, United States Department of Psychiatry, University of California, Riverside, Riverside, CA, United States Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA, United States Department of Anatomy, Howard University College of Medicine, Washington, DC, United States Department of Psychiatry, Yale University, New Haven, CT, United States Department of Psychiatry, School of Medicine, Texas Tech University Health Sciences Center, Midland, TX, United States Department of Psychiatry, Mt. Sinai University School of Medicine, New York, NY, United States Department of Clinical Psychology, St. John's University, Queens, NY, United States Correspondence: Kai-Uwe Lewandrowski, business@tucsonspine.com; Kenneth Blum, drd2gene@gmail.com 17 11 2025 2025 13 1737084 31 10 2025 03 11 2025 Copyright © 2025 Lewandrowski, Blum, Lewandrowski, Thanos, Pinhasov, Sharafshah, Baron, Gold, Dennen, Elman, Bowirrat, Modestino, Zeine, Jafari, Sunder, Makale, Giordano, Gondre-Lewis, Lindenau, Fuehrlein, Badgaiyan, Levin, Schmidt and Fiorelli. 2025 Lewandrowski, Blum, Lewandrowski, Thanos, Pinhasov, Sharafshah, Baron, Gold, Dennen, Elman, Bowirrat, Modestino, Zeine, Jafari, Sunder, Makale, Giordano, Gondre-Lewis, Lindenau, Fuehrlein, Badgaiyan, Levin, Schmidt and Fiorelli https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia by Lewandrowski, K.-U., Blum, K., Lewandrowski, A. P. L., Thanos, P. K., Pinhasov, A., Sharafshah, A., Baron, D., Gold, M. S., Dennen, C. A., Elman, I., Bowirrat, A., Modestino, E. J., Zeine, F., Jafari, N., Sunder, K., Makale, M. T., Giordano, J., Gondre-Lewis, M. C., Lindenau, M., Fuehrlein, B. S., Badgaiyan, R. D., Levin, C., Schmidt, S. L., and Fiorelli, R. K. A. (2025). Front. Public Health 13:1594872. doi: 10.3389/fpubh.2025.1594872 dopamine D2 receptor (DRD2) hypodopaminergia pro-dopaminergic therapy stress induced anxiety genetic predisposition Reward Deficiency Syndrome (RDS) neurotransmitter regulation addiction and mood disorders section-at-acceptance Substance Use Disorders and Behavioral Addictions

The title of this article was erroneously given as “Targeting pro-dopaminergic agonism to attenuate and depression in patient's displaying genetic/epigenetic predisposition to hypodopaminergia.”

The correct title of the article is “Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland